{"nctId":"NCT02284035","briefTitle":"Safety & Efficacy of Dual Therapy With Raltegravir/Lamivudine","startDateStruct":{"date":"2015-09-27","type":"ACTUAL"},"conditions":["AIDS"],"count":75,"armGroups":[{"label":"Group 1 Raltegravir / 3TC (MK0518B","type":"EXPERIMENTAL","interventionNames":["Drug: Raltegravir/3TC"]},{"label":"Group 2 standard combination therapy","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: EFV/TDF/FTC","Drug: ATV/r + TDF/FTC or DRV/r + TDF/FTC","Drug: DTG+ABC/3TC DTG+TDF/FTC EVG/cobi/TDF/FTC RAL+TDF/FTC","Drug: EFV plus ABC/3TC or RPV/TDF/FTC","Drug: ATV/r plus ABC/3TC","Drug: DRV/r + ABC/3TC or LPV/r + ABC/3TC or LPV/r + TDF/FTC","Drug: RAL plus ABC/3TC","Drug: Other ART regimens"]}],"interventions":[{"name":"Raltegravir/3TC","otherNames":[]},{"name":"EFV/TDF/FTC","otherNames":["NNRTI-Based Regimen"]},{"name":"ATV/r + TDF/FTC or DRV/r + TDF/FTC","otherNames":["PI-Based Regimens"]},{"name":"DTG+ABC/3TC DTG+TDF/FTC EVG/cobi/TDF/FTC RAL+TDF/FTC","otherNames":["INSTI-Based Regimens"]},{"name":"EFV plus ABC/3TC or RPV/TDF/FTC","otherNames":["NNRTI-Based Regimens"]},{"name":"ATV/r plus ABC/3TC","otherNames":["PI-Based Regimen"]},{"name":"DRV/r + ABC/3TC or LPV/r + ABC/3TC or LPV/r + TDF/FTC","otherNames":["PI-Based Regimens"]},{"name":"RAL plus ABC/3TC","otherNames":["INSTI-Based Regimen"]},{"name":"Other ART regimens","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Eligible patients will be males or females at least 18 years of age. Women of childbearing potential must have a negative pregnancy test within 10 days prior to randomization into the study.\n2. Patients seropositive for HIV-1 using standard diagnostic criteria.\n3. Patients virologically suppressed during at least 12 months prior to inclusion (viral load \\<50 copies/mL).\n4. Patients on combination antiretroviral therapy (at least 2 antiretroviral drugs) for at least 12 months before being randomized in this study.\n5. Patients who are clinically stable in the opinion of the investigator at study entry (clinical status and chronic medication must not have not been modified at least 14 days prior to randomization).\n6. Patients who have signed informed consent to participate in the study.\n\nExclusion Criteria:\n\n1. Pregnancy, lactation, or planned pregnancy during the study period.\n2. Previous failure to an integrase inhibitor-containing regimen.\n3. Previous failure to a 3TC or FTC-containing regimen.\n4. Resistance mutations to 3TC or integrase inhibitor if any resistance test had been previously performed.\n5. Any disease or history of disease which, in the opinion of the investigator, might confound the results of the study or pose additional risk to patient treatment.\n6. Chronic hepatitis B.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Proportion of Patients Free of Therapeutic Failure","description":"Proportion of patients free of therapeutic failure at week 24. Therapeutic failure includes virological failure, change in treatment for any reason, consent withdrawal, loss to follow-up or death","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47","spread":null},{"groupId":"OG001","value":"20","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null}]},{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]},{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Efficacy in Virological Suppression Assessed With Ultrasensitive HIV-1 RNA Detection (Limit of Detection 1 Copy/mL)","description":null,"classes":[]},{"type":"SECONDARY","title":"Changes in Peripheral Mononuclear Blood Cells HIV-1 Reservoir","description":null,"classes":[]},{"type":"SECONDARY","title":"Changes in Insulin Resistance (HOMA-IR)","description":"Composite measure","classes":[]},{"type":"SECONDARY","title":"Changes in Body Fat Composition","description":"Composite measure","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54.13","spread":"19.44"},{"groupId":"OG001","value":"49.43","spread":"21.26"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.50","spread":"7.62"},{"groupId":"OG001","value":"27.54","spread":"8.75"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"54.09","spread":"17.68"},{"groupId":"OG001","value":"50.21","spread":"23.77"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.84","spread":"7.23"},{"groupId":"OG001","value":"28.78","spread":"9.55"}]}]}]},{"type":"SECONDARY","title":"Changes in Plasma 25-OH Vitamin D Levels","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.4","spread":"9.0"},{"groupId":"OG001","value":"16.7","spread":"9.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.5","spread":"15.1"},{"groupId":"OG001","value":"26.5","spread":"17.2"}]}]}]},{"type":"SECONDARY","title":"Changes in Estimated Glomerular Filtration Rate (CKD-EPI)","description":"Composite measure","classes":[]},{"type":"SECONDARY","title":"Changes in CD38","description":null,"classes":[]},{"type":"SECONDARY","title":"Changes in IL-6","description":null,"classes":[]},{"type":"SECONDARY","title":"Changes in Sleep Quality (Pittsburgh Sleep Quality Index)","description":"The Pittsburgh Quality Index (PSQI) is an effective instrument used to measure the quality and patterns of sleep in adults. It differentiates \"poor\" from \"good\" sleep quality by measuring seven Ã¡reas (components): subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medications, and daytime dysfunction over the last month.\n\nThe posible range of the scale is from 0 to 21 points. The greater the score the poorest is the sleep quality.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":"3.5"},{"groupId":"OG001","value":"4.7","spread":"3.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.8","spread":"3.1"},{"groupId":"OG001","value":"5.1","spread":"3.5"}]}]}]},{"type":"SECONDARY","title":"Changes in Adherence in Both Treatment Arms (Morisky-Green Test)","description":"Patients were asked to complete the Morisky-Green questionnaire:\n\nSome people forget to take their medication as prescribed. How often does it happen to you? (Always/often/sometimes/rarely/never) Some people forget some taking of the medication or change the prescribed schedule / take to adapt it to their own needs. How often do you do it? (Always/often/sometimes/rarely/never) Some people stop taking their medications as prescribed when they feel better. How often do you do it? (Always/often/sometimes/rarely/never) Some people stop taking their medications as prescribed when they feel worse. How often do you do it? (Always/often/sometimes/rarely/never)\n\nOnly if patients answered never to each four questions, they were considered adherent; if not, non adherent.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"11","spread":null}]},{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"13","spread":null}]},{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"14","spread":null}]},{"measurements":[{"groupId":"OG000","value":"27","spread":null},{"groupId":"OG001","value":"5","spread":null}]},{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]}]},{"type":"SECONDARY","title":"Changes in Total Cholesterol","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"189","spread":"46"},{"groupId":"OG001","value":"187","spread":"44"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"190","spread":"45"},{"groupId":"OG001","value":"186","spread":"37"}]}]}]},{"type":"SECONDARY","title":"Changes in HDL Cholesterol","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48","spread":"15"},{"groupId":"OG001","value":"46","spread":"13"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49","spread":"14"},{"groupId":"OG001","value":"45","spread":"15"}]}]}]},{"type":"SECONDARY","title":"Changes in LDL Cholesterol","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"120","spread":"39"},{"groupId":"OG001","value":"115","spread":"29"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"119","spread":"40"},{"groupId":"OG001","value":"118","spread":"33"}]}]}]},{"type":"SECONDARY","title":"Changes in Triglycerides","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.5","spread":"49.9"},{"groupId":"OG001","value":"112.0","spread":"53.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.7","spread":"44.8"},{"groupId":"OG001","value":"100.9","spread":"37.3"}]}]}]},{"type":"SECONDARY","title":"Changes in Bone Mineral Density","description":"DEXA","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1166.1","spread":"100.9"},{"groupId":"OG001","value":"1211.6","spread":"79.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1183.0","spread":"98.5"},{"groupId":"OG001","value":"1247.4","spread":"80.9"}]}]}]},{"type":"SECONDARY","title":"Changes in Urine Beta-2-microglobulin/Creatinine Ratio","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"672.8","spread":"773.3"},{"groupId":"OG001","value":"595.3","spread":"948.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"275.7","spread":"227.2"},{"groupId":"OG001","value":"788.5","spread":"1587.3"}]}]}]},{"type":"SECONDARY","title":"Changes in HLA-DR","description":null,"classes":[]},{"type":"SECONDARY","title":"Changes in High Sensitivity C-reactive Protein","description":null,"classes":[]},{"type":"SECONDARY","title":"Changes in Mononuclear Activation SD-14","description":null,"classes":[]},{"type":"SECONDARY","title":"Changes in Mononuclear Activation SD-163","description":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":49},"commonTop":["Amigdalitis","Insomnia","Lues","Dizziness","Ansiety"]}}}